RevOps · healthcare · LATAMJul 202610 min read353 words

Pipeline forecasting for Series B companies: scaling without breaking for healthcare and life sciences in Latin America

How Series B companies scale pipeline forecasting across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install pipeline forecasting has to be shaped to that reality from day one.

Series B is the stress test for pipeline forecasting. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, forecast variance vs actuals per quarter, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Pipeline forecasting is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of pipeline forecasting is coverage ratios that reward pipeline theatre, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on forecast variance vs actuals per quarter outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run pipeline forecasting function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing pipeline forecasting deliberately for this market rather than importing a playbook designed for somewhere else.

pipeline forecastingsales forecastforecast accuracypipeline forecasting for series Bscaling GTMpipeline forecasting for healthcare and life sciencespipeline forecasting in Latin Americahealthcare and life sciences growth in Latin America

Frequently asked questions

RevOps · healthcare · LATAM — answered

Does pipeline forecasting work for healthcare and life sciences in Latin America?
Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
How does pipeline forecasting change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible forecast variance vs actuals per quarter.
What compensation model works for pipeline forecasting operators at Series B?
Outcome-linked on forecast variance vs actuals per quarter, not activity-based.
What is the Series B stress point?
Coverage ratios that reward pipeline theatre, amplified by headcount. Fix the root, not the symptom.
What is the LATAM-specific pitfall when running pipeline forecasting for healthcare?
Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.

Growth Broker editorial

Filed under revops · healthcare · latam

Up next

AI for Growth: the complete 2026 guide for B2B companies

Read piece

Ready to broker your growth?

Book a Growth Call